Clinical Trial Detail

NCT ID NCT02259231
Title RTA 408 Capsules in Patients With Melanoma - REVEAL
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Reata Pharmaceuticals, Inc.
Indications

melanoma

Therapies

Ipilimumab

Nivolumab

Omaveloxolone

Age Groups: adult

No variant requirements are available.